June 1st 2025
Results from the NIVOPOSTOP trial found improved DFS with adjuvant nivolumab plus cisplatin and RT for patients with LA-SCCHN.
Increased Risk of Second Malignancies With Radioactive Iodine Therapy for Thyroid Cancer
April 27th 2015A new population-based study has found that patients with thyroid cancer who are treated with radioactive iodine therapy are at increased risk for developing salivary cancer as a second malignancy.
Serum Biomarkers Could Aid in Early Diagnosis of HNSCC
November 23rd 2013A small retrospective study has identified several biomarkers that were significantly altered in patients with head and neck squamous cell carcinoma. If further validated, these serum biomarkers could facilitate early diagnosis.
Identifying Oropharyngeal Cancer Patients Who Require PEG Tube During Chemo
October 31st 2013Researchers have identified several risk factors that may help predict which patients with oropharyngeal cancer may require a percutaneous endoscopic gastrostomy tube during chemoradiotherapy, according to a newly published review.
Study: HNSCC Outcomes in Blacks Similar to Whites
October 28th 2013Black race did not adversely affect outcomes after receiving radiotherapy for head and neck squamous cell carcinoma compared with white race, according to the results of a study in which black patients made up the majority of enrolled participants.
ECC: Hyperfractionated Radiotherapy Improved Survival for Head and Neck Cancers
October 2nd 2013The use of altered fractionation radiotherapy increased overall survival in patients with locally advanced head and neck cancers when compared with standard radiation, according to the results of a meta-analysis presented on Saturday at the 2013 European Cancer Congress in Amsterdam.
In Intermediate-Risk Nasopharyngeal Cancers, PET/CT Appropriate for Detecting Distant Metastases
August 23rd 2013Researchers in China have found that the use of [18F] fluorodeoxyglucose PET/CT detected a greater number of distant metastases than conventional work-up imaging in patients with nasopharyngeal carcinoma.
Escitalopram for Head and Neck Cancer Patients Cut Depression in Half
June 25th 2013Prophylactic use of the SSRI escitalopram decreased the occurrence of depression in patients with head and neck cancers by 50% and resulted in significantly improved quality of life for 3 months after drug cessation, according to the results of the PROTECT trial.
Locoregional Recurrence of an HPV-Positive Squamous Cell Carcinoma of the Head and Neck
Locoregional recurrences are a major source of morbidity and mortality for patients with squamous cell carcinomas of the head and neck (HNSCC).
Latest PARSPORT Results Confirm: IMRT Greatly Reduces Treatment Effects in Head and Neck Cancer
January 19th 2011Two-year results from the largest randomized trial of IMRT in head and neck cancer confirm that it dramatically reduces the risk of dysphagia and xerostomia. The study was too small to establish a survival advantage, although the results are encouraging.
A Shifting Paradigm for Patients with Head and Neck Cancer: Transoral Robotic Surgery (TORS)
October 15th 2010This paper by Drs. Bhayani, Holsinger, and Lai describes a new approach to an old problem. Advances in the management of head and neck cancer over the past few decades have been made predominantly in the area of non-surgical therapy. Starting with the Veterans Affairs Cooperative Trial for laryngeal cancer in the early 1990’s,[1] advances in the administration of chemotherapy and radiation therapy have enabled patients to forego traditional extensive resections that compromised speech and swallowing function.[2] The advances in combined chemoradiation for advanced head and neck cancer have come with a detriment to some patients in survival and quality of life.[3] Effective treatment, but with decreased morbidity was needed.